ClinicalTrials.gg
RecruitingNCT04265040TORCH-PlusUpdated Nov 30, 2023

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies

An observational study in Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy and HCM - Hypertrophic Cardiomyopathy, sponsored by University Hospital Heidelberg. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-30.

Sponsored by University Hospital Heidelberg · Observational

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,040
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cardiomyopathy, Dilated with a site in Germany — 4 open to participants now, 5 under way, none of them phase 3. Cardiomyopathy, Dilated · Germany.

Planned enrollment
4th of 11
2,040 · median 750
Started
2020
with 4 others
Observational
11 of 23
3 open now
Registered
16th of 23
by date
Lead sponsor
3 of 23
University Hospital Heidelberg

Among the 23 studies in Cardiomyopathy, Dilated with a site in Germany, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2020, is one of 11 observational ones, and was the 16th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

4 of the 23 studies in Cardiomyopathy, Dilated with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cardiomyopathy, Dilated with a site in Germany, or all of them as a file.
02

Study summary

The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity.

This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. "Clinical phenotyping, follow-up \& biosampling" 2. "Genomics", 3. "Inflammation" and 4. "Biomarker". The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for outcome, 5) to validate novel biomarkers developed in other DZHK studies, and 6) to foster active cooperation with international CMP registries and partners from industry.

03

Conditions studied

  • Non-ischemic Cardiomyopathy
  • DCM - Dilated Cardiomyopathy
  • HCM - Hypertrophic Cardiomyopathy
  • HOCM - Hypertrophic Obstructive Cardiomyopathy
  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Left Ventricular Noncompaction Cardiomyopathy
  • Amyloidosis
  • Inflammatory Cardiomyopathy

Keywords

  • Cardiomyopathies, registry, data, biomaterial, genetics
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-ischemic structural cardiomyopathies
  • Age ≥ 18 or ≤ 80 years
  • The patient is able to understand the declaration of consent and to sign it dated
  • At least one of the following diagnoses depending on the specific TORCH-

Plus inclusion / exclusion - SOP:

Dilated Cardiomyopathy (DCM)

  • family / genetic
  • inflammatory / persistent myocarditis
  • idiopathic (after exclusion secondary cause)
  • left sided systolic dysfunction (EF ≤ 45%)

Left ventricular hypertrophy

  • sarcomere hypertrophic cardiomoypathia (HCM, HOCM)
  • amyloid (AL: light chains, TTR: transthyretin, wild type)

Left ventricular non-compaction cardiomyopathy (LVNC)

Arrhythmogenic right ventricular cardiomyopathy (ARVC / D)

Exclusion criteria

Exclusion Criteria:

The following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion / exclusion - SOP in detail:

  • Age: \<18 years or> 80 years
  • Patient has other (cardiac) previous illnesses:

    • uncontrollable arterial hypertension
    • primary pulmonary arterial hypertension
    • radiation therapy in the chest area
    • addiction (drug or alcohol abuse)
    • \<1 year due to non-cardiological pre-existing conditions
    • significant heart valve disease
    • ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly)
    • chemotoxic cardiomyopathy
    • condition after myocarditis
    • combination of several traditional risk factors (e.g. hypertension and diabetes mellitus)
    • advanced chronic non-cardiac disease (e.g. chronic hepatitis or )
    • Tachymyopathy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,040 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. all-cause mortality

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2027, 88 months after the start.

Of 51 observational studies under Cardiomyopathy, Dilated, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 101. This study's planned 88 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2020
First posted
Feb 11, 2020
StartActual
Aug 18, 2020
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04265040
Collaborators
University Medicine Greifswald, Charite University, Berlin, Germany, German Heart Center, University of Mannheim, University Hospital Schleswig-Holstein, Medical University of Hannover, Goethe University, Universitätsklinikum Hamburg-Eppendorf, University Medical Center Mainz, University Medical Center Goettingen, Deutsches Herzzentrum Muenchen, Technical University of Munich, University Hospital Munich, Kerckhoff Klinik
Responsible party
Benjamin Meder (Deputy Director - Clinic of Cardiology, Angiology and Pneumology, University Hospital Heidelberg) — Principal investigator
First posted
Feb 11, 2020
Start date
Aug 18, 2020
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 30, 2023

Study contacts

Farbod Sedaghat-Hamendani, Dr.
Contact
Farbod.Sedaghat-Hamedani@med.uni-heidelberg.de
+496221/56-8676
Johannes Trebing, Dr.
Contact
Johannes.Trebing@med.uni-heidelberg.de

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion